Literature DB >> 25881000

Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors.

Maxime Ferrand1, Sylvie Da Rocha1, Guillaume Corre1, Anne Galy2, Florence Boisgerault3.   

Abstract

The immunogenic properties of recombinant adeno-associated virus (rAAV) gene transfer vectors remain incompletely characterized in spite of their usage as gene therapy vectors or as vaccines. Molecular interactions between rAAV and various types of antigen-presenting cells (APCs), as well as the impact of these interactions on transgene or capsid-specific immunization remain unclear. We herein show that binding motifs recognized by the capsid and which determine the vector tissue tropism are also critical for key immune activation processes. Using rAAV capsid serotype 1 (rAAV1) vectors which primary receptors on target cells are α2,3 and α2,6 N-linked sialic acids, we show that sialic acid-dependent binding of rAAV1 on APCs is essential to trigger CD4(+) T-cell responses by increasing rAAV1 uptake and contributing to antigenic presentation of both the capsid and transgene product although this involves different APCs. In addition, the nanoparticulate structure of the vector in itself appears to be sufficient to trigger mobilization and activation of some APCs. Therefore, combinations of structural and of serotype-specific cell-targeting properties of rAAV1 determine its complex immunogenicity. These findings may be useful to guide a selection of rAAV variants depending on the intended level of immunogenicity for either gene therapy or vaccination applications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25881000      PMCID: PMC4817752          DOI: 10.1038/mt.2015.59

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  51 in total

Review 1.  CD169+ macrophages at the crossroads of antigen presentation.

Authors:  Luisa Martinez-Pomares; Siamon Gordon
Journal:  Trends Immunol       Date:  2011-12-21       Impact factor: 16.687

Review 2.  Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.

Authors:  Rebecca Klippstein; David Pozo
Journal:  Nanomedicine       Date:  2010-01-18       Impact factor: 5.307

3.  Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation.

Authors:  Susanne A Keller; Katrin Schwarz; Vania Manolova; Caroline E von Allmen; Matthias G Kinzler; Monika Bauer; Simone Muntwiler; Philippe Saudan; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

Review 4.  The sweet spot: defining virus-sialic acid interactions.

Authors:  Jennifer E Stencel-Baerenwald; Kerstin Reiss; Dirk M Reiter; Thilo Stehle; Terence S Dermody
Journal:  Nat Rev Microbiol       Date:  2014-09-29       Impact factor: 60.633

5.  Amino-functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages.

Authors:  Oleg Lunov; Tatiana Syrovets; Cornelia Loos; G Ulrich Nienhaus; Volker Mailänder; Katharina Landfester; Mustapha Rouis; Thomas Simmet
Journal:  ACS Nano       Date:  2011-12-08       Impact factor: 15.881

6.  Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.

Authors:  Aurélie Goyenvalle; Adeline Vulin; Françoise Fougerousse; France Leturcq; Jean-Claude Kaplan; Luis Garcia; Olivier Danos
Journal:  Science       Date:  2004-11-04       Impact factor: 47.728

7.  Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes.

Authors:  Takashi Okada; Mutsuko Nonaka-Sarukawa; Ryosuke Uchibori; Kazue Kinoshita; Hiromi Hayashita-Kinoh; Yuko Nitahara-Kasahara; Shin'ichi Takeda; Keiya Ozawa
Journal:  Hum Gene Ther       Date:  2009-09       Impact factor: 5.695

Review 8.  Adeno-associated virus vectors: immunobiology and potential use for immune modulation.

Authors:  Grant J Logan; Ian E Alexander
Journal:  Curr Gene Ther       Date:  2012-08       Impact factor: 4.391

9.  Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.

Authors:  Christian Mueller; Jeffrey D Chulay; Bruce C Trapnell; Margaret Humphries; Brenna Carey; Robert A Sandhaus; Noel G McElvaney; Louis Messina; Qiushi Tang; Farshid N Rouhani; Martha Campbell-Thompson; Ann Dongtao Fu; Anthony Yachnis; David R Knop; Guo-Jie Ye; Mark Brantly; Roberto Calcedo; Suryanarayan Somanathan; Lee P Richman; Robert H Vonderheide; Maigan A Hulme; Todd M Brusko; James M Wilson; Terence R Flotte
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 19.456

Review 10.  Dendritic cells: a spot on sialic Acid.

Authors:  Hélio J Crespo; Joseph T Y Lau; Paula A Videira
Journal:  Front Immunol       Date:  2013-12-27       Impact factor: 7.561

View more
  4 in total

1.  Nanochannel-Based Poration Drives Benign and Effective Nonviral Gene Delivery to Peripheral Nerve Tissue.

Authors:  Jordan T Moore; Christopher G Wier; Luke R Lemmerman; Lilibeth Ortega-Pineda; Daniel J Dodd; William R Lawrence; Silvia Duarte-Sanmiguel; Kavya Dathathreya; Ludmila Diaz-Starokozheva; Hallie N Harris; Chandan K Sen; Ian L Valerio; Natalia Higuita-Castro; William David Arnold; Stephen J Kolb; Daniel Gallego-Perez
Journal:  Adv Biosyst       Date:  2020-09-16

2.  Early Intervention in Ischemic Tissue with Oxygen Nanocarriers Enables Successful Implementation of Restorative Cell Therapies.

Authors:  Ludmila Diaz-Starokozheva; Devleena Das; Xiangming Gu; Jordan T Moore; Luke R Lemmerman; Ian Valerio; Heather M Powell; Natalia Higuita-Castro; Michael R Go; Andre F Palmer; Daniel Gallego-Perez
Journal:  Cell Mol Bioeng       Date:  2020-05-29       Impact factor: 2.321

Review 3.  Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.

Authors:  Michael F Naso; Brian Tomkowicz; William L Perry; William R Strohl
Journal:  BioDrugs       Date:  2017-08       Impact factor: 5.807

4.  Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.

Authors:  Zachary Fitzpatrick; Christian Leborgne; Elena Barbon; Elisa Masat; Giuseppe Ronzitti; Laetitia van Wittenberghe; Alban Vignaud; Fanny Collaud; Séverine Charles; Marcelo Simon Sola; Fabienne Jouen; Olivier Boyer; Federico Mingozzi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-13       Impact factor: 6.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.